Cholinesterase inhibitor use in Alzheimer's disease: The EPIFARM-Elderly Project

Pharmacoepidemiology and Drug Safety

Volumn 20, Issue 5, 2011, Pages 497-505

  Franchi, Carlotta ^a   Lucca, Ugo ^a   Tettamanti, Mauro ^a   Riva, Emma ^a   Fortino, Ida ^b   Bortolotti, Angela ^b   Merlino, Luca ^b   Pasina, Luca ^a   Nobili, Alessandro ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b Regional Health Ministry   (Italy)

Author keywords

Alzheimer's disease; Cholinesterase inhibitors; Drug utilization study

Indexed keywords

CHOLINESTERASE INHIBITOR;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; DISEASE SEVERITY; DRUG UTILIZATION; ELDERLY CARE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT DURATION;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; DRUG PRESCRIPTIONS; DRUG UTILIZATION REVIEW; FEMALE; HEALTH SERVICES FOR THE AGED; HUMANS; INCIDENCE; ITALY; MALE; PREVALENCE; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES;

EID: 79955132362     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.2124     Document Type: Article

References (42)

1. ADI. World Alzheimer Report. Alzheimer's Disease International: London, 2009; 1-92.
2. Fratiglioni L, De Ronchi D, Agüero-Torres H. Worldwide prevalence and incidence of dementia. Drugs Aging 1999; 15(5): 365-375.
3. Davis KL, Thal LJ, Gamzu ER, et al. A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. N Engl J Med 1992; 327: 1253-1259.
4. Farlow M, Gracon SI, Hershey LA, et al. A controller trial of tacrine in Alzheimer's disease. JAMA 1992; 268: 2523-2529.
5. Knapp MJ, Knopman DS, Solomon PR, et al. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. JAMA 1994; 271: 985-991.
6. Lanctot KL, Herrmann N, Yau KK, et al. Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis. CMAJ 2003; 169: 557-564.
7. Kaduszkiewicz H, Zimmermann T, Beck-Bornholdt HP, et al. Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials. BMJ 2005; 331: 321-327.
8. Oude Voshaar RC, Burns A, Olde Rikkert MG. Alarming arbitrariness in EU prescription and reimbursement criteria for anti-dementia drugs. Int J Geriatr Psychiatry 2006; 21: 29-31.
9. Pariente A, Helmer C, von Merliere Y, Moore N, Fourrier-Réglat A, Dartigues JF. Prevalence of cholinesterase inhibitors in subjects with dementia in Europe. Pharmacoepidemiol Drug Saf 2008; 17: 655-660.
10. Le Note AIFA. Nota AIFA 85. URL [accessed on 28 October 2009]
11. Lucca U, Nobili A, Riva E, Tettamanti M. Cholinesterase inhibitor use and age in the general population. Arch Neurol 2006; 63(1): 154-155.
12. Percudani M, Barbui C, Fortino I, Petrovich L. Antidepressant drug use in Lombardy, Italy: a population-based study. J Affect Disord 2004; 83: 169-175.
13. Italian Ministry of Health. Protocollo di monitoraggio dei piani di trattamento farmacologico per la malattia di Alzheimer. D. M. del 20/07/2000, S. O. alla G. U. n. 204 del 01/09/2000, e D. M. del 14/03/2001, G. U. n. 86 del 12/04/2001. Supplemento ordinario alla G. U. n. 204 del 1 Settembre 2000-Serie Generale.
14. Ravaglia G, Forti P, Maioli F, et al. Incidence and etiology of dementia in a large elderly Italian population. Neurology 2005; 64: 1525-1530.
15. Lucca U, Garrì M, Nobili A, et al. Risk of dementia continues to rise in the oldest old: the Monzino 80-plus study. Alzheimers Dement 2009; 5: 381.
16. Tettamanti M, Nobili A, Riva E, Lucca U, DIGIS Study Group. A three-year observational study on efficacy and safety of donepezil in Alzheimer dementia. Alzheimer Dement 2006; 2(3): S79.
17. Cuzick J. A Wilcoxon-type test for trend. Stat Med 1985; 4: 87-90.
18. Raschetti R, Maggini M, Sorrentino GC, Martini N, Caffari B, Vanacore N. A cohort study of effectiveness of acetylcholinesterase inhibitors in Alzheimer's disease. Eur J Clin Pharmacol 2005; 61(5-6): 361-368.
19. Crismon ML. Tacrine: first drug approved for Alzheimer's disease. Ann Pharmacother 1994; 28(6): 744-751.
20. AD2000 Collaborative Group. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial. Lancet 2004; 363(9427): 2105-2115.
21. Hoffman F, van den Bussche H, Glaeske G, Kaduszkiewicz H. Eight-year prescription trends of memantine and cholinesterase inhibitors among persons 65years and older in Germany. Int Clin Psychopharmacol 2010; 25: 29-36.
22. Herrmann N, Gill SS, Bell CM, et al. A population-based study of cholinesterase inhibitor use for dementia. JAGS 2007; 55: 1517-1523.
23. Italian Medicines Agency and Italian Ministry of Health. Progetto CRONOS: i risultati dello studio osservazionale. BIF: Aggiornamenti. 2004; 5-6: 183-188.
24. Mucha L, Wang SS, Cuffel B, McRae T, Mark LT, del Valle M. Comparison of cholinesterase inhibitor utilization patterns and associated health care costs in Alzheimer's disease. JMCP 2008; 14(5): 451-461.
25. Alva G, Cummings JL. Relative tolerability of Alzheimer's disease treatments. Psychiatry 2008; 5: 27-36.
26. Lucca U, Tediosi F, Tettamenti M. Epidemiologic Dimension and Economic Impact of Dementia in Italy (In Italian). Milan: Emme Edizioni, 2001.
27. Hebert LE, Scherr PA, Bienias JL, Bennet DA, Evans DA. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol 2003; 60: 1119-1122.
28. Feldman H, Gauthier S, Hecker J, et al. Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo-controlled trial. Int J Geriatr Psychiatry 2005; 20: 559-569.
29. Winblad B, Kilander L, Eriksson S, et al. Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study trial. Lancet 2006; 367: 1057-1065.
30. Schneider Ls, Anand R, Farlow MR. Systematic review of the efficacy of rivastigmine for patients with Alzheimer's disease. Intl J Geriatr Psychopharmacol 1998; 1: S26-S34.
31. Sing G, Thomas SK, Arcona S, et al. Treatment persistence with rivastigmine and donepezil in a large state medicaid program. J Am Geriatr Soc 2005; 53: 1269-1270.
32. Suh DC, Thomas SK, Valiyeva E, et al. Drug persistency of two cholinesterase inhibitors: rivastigmine versus donepezil in elderly patients with Alzheimer's disease. Drugs Aging 2005; 22: 695-707.
33. Mohs RC, Doody RS, Morris JC, et al. A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology 2001; 57: 488-488.
34. Winblad B, Engedal K, Soininen H, et al. A 1-year, randomised, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 2001; 57: 489-495.
35. Raskind MA, Peskind ER, Truyen L, et al. The cognitive benefit of galantamine are sustained for at least 36 months: a long-term extension trial. Arch Neurol 2004; 61: 252-256.
36. Doody RS, Gelmacher DS, Gordon B, et al. Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. Arch Neurol 2001; 58: 427-433.
37. Farlow MR, Lilly ML. Rivastigmine: an open-label, observational study of safety and effectiveness in treating patients with Alzheimer's disease for up to 5years. BMC Geriatr 2005; 5: 3.
38. OSMED. L'uso dei farmaci in Italia. Rapporto Nazionale Anno 2007. Osservatorio Nazionale sull'Impiego dei Medicinali: Rome, 2007.
39. Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius H. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 2003; 348: 1333-1341.
40. Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 2004; 291: 317-324.
41. NICE. 2007. Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease. National Institute for Health and Clinical Excellence: London. Technology appraisal guidance no. 111. URL [accessed on June 14, 2010]
42. Sabbagh MN. Drug development for Alzheimer's disease: where are we now and where are we headed? Am J Geriatr Pharmacother 2009; 7: 167-185.